Aimmune Therapeutics Inc. (AIMT) Rating Reiterated by Wedbush
Aimmune Therapeutics Inc. (NASDAQ:AIMT)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research report issued on Wednesday. They presently have a $42.00 price objective on the stock. Wedbush’s price target points to a potential upside of 165.65% from the company’s previous close.
Other equities analysts have also issued reports about the company. Credit Suisse Group AG reissued a “buy” rating and set a $35.00 price target on shares of Aimmune Therapeutics in a research note on Friday, August 19th. Zacks Investment Research raised Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $38.00 price objective on shares of Aimmune Therapeutics in a research note on Wednesday, June 29th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $32.75.
Shares of Aimmune Therapeutics (NASDAQ:AIMT) opened at 15.81 on Wednesday. Aimmune Therapeutics has a 52-week low of $9.77 and a 52-week high of $26.50. The company’s 50 day moving average price is $14.40 and its 200 day moving average price is $13.61. The company’s market capitalization is $668.04 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/aimmune-therapeutics-inc-aimt-rating-reiterated-by-wedbush-2.html
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.01. On average, analysts predict that Aimmune Therapeutics will post ($1.71) EPS for the current year.
In other news, insider Mary M. Rozenman sold 30,000 shares of the stock in a transaction that occurred on Thursday, September 8th. The stock was sold at an average price of $16.80, for a total value of $504,000.00. Following the sale, the insider now directly owns 30,000 shares in the company, valued at $504,000. The sale was disclosed in a document filed with the SEC, which is available at this link. 24.56% of the stock is owned by insiders.
Several large investors have recently modified their holdings of AIMT. Metropolitan Life Insurance Co. NY increased its stake in shares of Aimmune Therapeutics by 9.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 9,617 shares of the company’s stock valued at $130,000 after buying an additional 797 shares during the last quarter. Emerald Acquisition Ltd. acquired a new stake in shares of Aimmune Therapeutics during the second quarter valued at $154,000. American International Group Inc. increased its stake in shares of Aimmune Therapeutics by 135.7% in the second quarter. American International Group Inc. now owns 15,131 shares of the company’s stock valued at $164,000 after buying an additional 8,711 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Aimmune Therapeutics during the first quarter valued at $212,000. Finally, Nationwide Fund Advisors increased its stake in shares of Aimmune Therapeutics by 127.7% in the second quarter. Nationwide Fund Advisors now owns 16,929 shares of the company’s stock valued at $183,000 after buying an additional 9,495 shares during the last quarter. Hedge funds and other institutional investors own 68.87% of the company’s stock.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.